No Data
The Market Doesn't Like What It Sees From Thalys Medical Technology Group Corporation's (SHSE:603716) Revenues Yet As Shares Tumble 26%
Thalys Medical Technology Group Corporation (603716.SH): The AI + digital therapy model for psychiatric medicine developed in collaboration with Huawei has not yet been officially released.
On February 28, Glorious Financial reported that Thalys Medical Technology Group Corporation (603716.SH) stated on the investor interaction platform that the collaboration with Huawei Technologies Co., Ltd. (hereinafter referred to as "Huawei") and the National Key Laboratory of Brain-Computer Intelligence (hereinafter referred to as "the Laboratory") mainly focuses on the precise diagnosis and treatment of mental disorders, especially the application of AI in digital therapies for psychiatry. In 2023, the company launched the digital mental health treatment product "Haisi Lingxi," developed in cooperation with the Mental Health Center of Zhejiang University First Hospital. Currently, the project team is integrating the Laboratory's clinical resources with Huawei's computing power and AIGC technology based on this product.
Thalys Medical Technology Group Corporation's (SHSE:603716) Shares Bounce 53% But Its Business Still Trails The Industry
2024 Earnings Advance Loss Announcement
Thalys Medical Technology Group Corporation (603716.SH): A forecasted loss of 0.21 billion to 0.25 billion yuan in 2024.
On January 17, Gelonghui reported that Thalys Medical Technology Group Corporation (603716.SH) announced an expected annual performance loss for 2024, estimating that the net income attributable to shareholders of the listed company will be between -0.21 billion yuan and -0.25 billion yuan in 2024; it is expected that the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses will be between -0.145 billion yuan and -0.19 billion yuan in 2024.
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): Currently, the company has no equity cooperation with Thalys Medical Technology Group Corporation.
On December 11, Gelonghui reported that China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated on the investor interaction platform that the company currently has no equity cooperation with Thalys Medical Technology Group Corporation.
